{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:31:24Z","timestamp":1789443084675,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ijantimicag.2008.06.032","type":"journal-article","created":{"date-parts":[[2008,9,14]],"date-time":"2008-09-14T09:56:13Z","timestamp":1221386173000},"page":"468-474","source":"Crossref","is-referenced-by-count":27,"title":["Clinical studies of garenoxacin"],"prefix":"10.1016","volume":"32","author":[{"given":"Hiroyasu","family":"Takagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3A","key":"10.1016\/j.ijantimicag.2008.06.032_bib1","first-page":"39S","article-title":"Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern","volume":"117","author":"File","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib2","first-page":"344","article-title":"Management of acute rhinosinusitis, bronchitis syndromes, and acute otitis media","volume":"5","author":"Jain","year":"2005","journal-title":"Adv Stud Med"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2005.12.008","article-title":"Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999\u20132003)","volume":"56","author":"Johnson","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2008.06.032_bib4","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.1086\/421352","article-title":"Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US\u2014an update","volume":"39","author":"Karchmer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib5","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","article-title":"Levofloxacin: a review of its use in the treatment of bacterial infections in the United States","volume":"63","author":"Croom","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib6","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/AAC.43.5.1077","article-title":"In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone","volume":"43","author":"Takahata","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib7","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/AAC.44.12.3351-3356.2000","article-title":"Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756","volume":"44","author":"Fung-Tomc","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/AAC.45.1.312-315.2001","article-title":"In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae","volume":"45","author":"Takahata","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib9","first-page":"903","article-title":"Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756)","volume":"52","author":"Hayashi","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib10","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/AAC.47.7.2327-2329.2003","article-title":"Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae","volume":"47","author":"Ameyama","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib11","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0378-4274(01)00509-4","article-title":"Clinical toxicological aspects of fluoroquinolones","volume":"127","author":"Stahlmann","year":"2002","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1592\/phco.21.20.1468.34482","article-title":"Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin","volume":"21","author":"Frothingham","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib13","first-page":"521","article-title":"Analysis of patients with hypoglycemia and\/or hyperglycemia induced by gatifloxacin: risk factors and patient profiles","volume":"52","author":"Tamayama","year":"2004","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkg209","article-title":"Adverse drug reactions: implications for the development of fluoroquinolones","volume":"51","author":"Ball","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2131\/jts.27.219","article-title":"Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs","volume":"27","author":"Nagai","year":"2002","journal-title":"J Toxicol Sci"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2131\/jts.28.35","article-title":"Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system","volume":"28","author":"Nakamura","year":"2003","journal-title":"J Toxicol Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib17","first-page":"42","article-title":"Three-month repeated oral dose toxicity study of garenoxacin in cynomolgus monkeys","volume":"55","author":"Kizawa","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib18","first-page":"1","article-title":"In vitro antibacterial activity of garenoxacin","volume":"55","author":"Takahata","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib19","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. M100-S17. Wayne, PA, CLSI, 2007. pp. 126\u20138."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib20","first-page":"95","article-title":"Phase I clinical studies of oral garenoxacin in healthy Japanese adult subjects","volume":"55","author":"Uchida","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib21","unstructured":"C\u00f6mezo\u011flu SN, Everett DW, Bonacorsi S, Bello A, Huczko E, Barrett JF, et al. Biotransformation of [14C]-BMS-284756 in man. In: American Association of Pharmaceutical Scientists (AAPS) Annual Meeting. 21\u201325 October 2001, Denver, CO, Poster #B191a."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib22","first-page":"162","article-title":"Penetration into sputum study of garenoxacin in patients with secondary infection of chronic respiratory disease","volume":"55","author":"Watanabe","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib23","first-page":"194","article-title":"Clinical phase III open-label study of oral garenoxacin in patients with otorhinolaryngological infection","volume":"55","author":"Baba","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2008.06.032_bib24","first-page":"372","article-title":"Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections","volume":"47","author":"Baba","year":"1999","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib25","first-page":"87","article-title":"In vitro metabolism and the effect on human cytochrome P450s of garenoxacin","volume":"55","author":"Nakamura","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib26","first-page":"116","article-title":"Clinical phase II study of garenoxacin in patients with respiratory tract infections\u2014open-label, multi-center, non-comparative","volume":"55","author":"Kobayashi","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/dkg017","article-title":"Impact of AUC\/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones","volume":"51","author":"Lister","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3999\/jscpt.23.515","article-title":"Phase I study of levofloxacin, (S)-(\u2212)-ofloxacin","volume":"23","author":"Nakashima","year":"1992","journal-title":"Jpn J Clin Pharmacol Ther"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib29","first-page":"1029","article-title":"Safety, pharmacokinetics and influence on the intestinal flora of BAY 12-8039 (moxifloxacin hydrochloride) after oral administration in healthy male subjects","volume":"33","author":"Ohnishi","year":"2005","journal-title":"Jpn Pharmacol Ther"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2008.06.032_bib30","first-page":"175","article-title":"Phase I study of gatifloxacin, a new quinolone I. Single-dose study","volume":"47","author":"Nakashima","year":"1999","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10096-003-0907-5","article-title":"In vitro antibacterial activity and pharmacodynamics of new quinolones","volume":"22","author":"Dalhoff","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib32","unstructured":"Tanigawara Y, Kasai H, Nozawa K. Population pharmacokinetic analysis and Monte Carlo pharmacodynamic simulations of a new quinolone, T-3811ME (garenoxacin). In: The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14\u201317 September 2003, Chicago, IL. Abstract A-6."},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib33","first-page":"144","article-title":"Phase III study of garenoxacin in patients with secondary infection of chronic respiratory disease","volume":"55","author":"Kobayashi","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib34","first-page":"127","article-title":"Clinical phase III comparative study on garenoxacin versus levofloxacin in patients with bacterial pneumonia","volume":"55","author":"Kobayashi","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib35","first-page":"185","article-title":"Clinical phase III open-labeled study of oral garenoxacin in patients with respiratory tract infection by penicillin-resistant Streptococcus pneumoniae","volume":"55","author":"Kohno","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2008.06.032_bib36","first-page":"214","article-title":"Relationship between oral administration of garenoxacin and QT interval","volume":"55","author":"Murakawa","year":"2007","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkg321","article-title":"The Alexander Project 1998\u20132000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents","volume":"52","author":"Jacobs","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0732-8893(03)00002-6","article-title":"Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999\u20132001)","volume":"45","author":"Jones","year":"2003","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib39","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1086\/430829","article-title":"A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance","volume":"41","author":"Fuller","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"Suppl. S1","key":"10.1016\/j.ijantimicag.2008.06.032_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/dkf810","article-title":"The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections","volume":"50","author":"Hoban","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib41","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijantimicag.2004.09.016","article-title":"Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002\u20132003. Results of the multinational GRASP Surveillance Program","volume":"25","author":"Beekmann","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib42","first-page":"712","article-title":"A double-blind comparative study of gatifloxacin and levofloxacin in pneumonia","volume":"47","author":"Saito","year":"1999","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"},{"key":"10.1016\/j.ijantimicag.2008.06.032_bib43","first-page":"734","article-title":"A double-blind comparative study of gatifloxacin and levofloxacin in chronic respiratory tract infections","volume":"47","author":"Saito","year":"1999","journal-title":"Nippon Kagaku Ryoho Gakkai Zasshi"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857908003087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T08:09:38Z","timestamp":1588925378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857908003087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0924857908003087"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.06.032","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}